Articles tagged with: Revlimid


[ by | Feb 29, 2012 2:15 pm | 2 Comments ]
Revlimid May Boost Vaccine Responses In Multiple Myeloma Patients

Results of a small study recently conducted at Johns Hopkins University indicate that Revlimid may boost vaccine responses in multiple myeloma patients.

Based on these results, the researchers who organized the study believe Revlimid could be used as part of a strategy to increase immune responses against both cancer and infectious diseases.

The researchers also argue that Revlimid may help reduce infections in myeloma patients being treated with the drug.  Infections are an important challenge for myeloma patients due to the immune system dysfunction that develops during the course of …

Read the full story »


[ by and | Feb 10, 2012 11:28 am | 6 Comments ]
Sequence Of Velcade And Revlimid Treatment May Not Matter In Many Multiple Myeloma Patients (ASH 2011)

The results of a recent retrospective analysis show that the sequence of treatment with Velcade and Revlimid may not have a significant effect on outcomes in multiple myeloma patients.

Only patients with kidney disease had significantly longer survival times if they received Velcade first.

The researchers from the Moffitt Cancer Center in Tampa, Florida, who conducted the analysis pointed out that further prospective trials are needed to confirm their findings.

The results were presented during a poster session at the 2011 American Society of Hematology (ASH) annual meeting in December. …

Read the full story »


[ by and | Feb 1, 2012 5:16 pm | 8 Comments ]
Experts Publish Consensus Statement On Maintenance Therapy In Multiple Myeloma

A group of myeloma experts from the International Myeloma Working Group recently published a consensus statement on maintenance therapies for myeloma patients.

In their statement, the experts reviewed the main findings from previous clinical trials that investigated the impact of maintenance therapies containing the novel agents thalidomide (Thalomid), Revlimid (lenalidomide), and Velcade (bortezomib).

Maintenance therapy is a prolonged, and often low-dose, form of treatment given to myeloma patients after their initial therapy. The goal of maintenance therapy is to prevent disease progression for as long as possible …

Read the full story »


[ by and | Jan 9, 2012 3:32 pm | Comments Off ]
Revlimid-Dexamethasone Combination Delays Disease Progression In Patients With Smoldering Multiple Myeloma (ASH 2011)

The most recent results of a Spanish Phase 3 clinical trial indicate that Revlimid in combination with dexamethasone delays disease progression in smoldering multiple myeloma patients who have a high risk of developing symptomatic disease.

Specifically, the results showed that high-risk smoldering multiple myeloma patients who received Revlimid plus dexamethasone had a longer time to disease progression and better overall survival than patients who did not receive treatment.

However, the Spanish researchers acknowledged that these results should be confirmed by long-term follow-up data, especially regarding the difference in overall survival. …

Read the full story »


[ by | Dec 28, 2011 4:50 pm | 2 Comments ]
ASH 2011 – The Meeting’s Myeloma-Related “Hidden Gem”

What were the myeloma-related "hidden gems" of the recent American Society of Hematology (ASH) annual meeting, which ended two weeks ago?

The Beacon asked exactly this question of its Medical Advisors -- the myeloma specialists who generously share their knowledge and expertise in the Beacon's myeloma discussion forum.

And the responses from the Advisors were surprising.

Surprising, because they were so similar.

The three Advisors who responded to the Beacon's question indepen­dently picked the same "hidden gem" -- specifically, the research presented at the meeting showing that …

Read the full story »